quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:12:22·37d
INSIDERFiling
Amphastar Pharmaceuticals Inc. logo

CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. covered exercise/tax liability with 12,692 shares, decreasing direct ownership by 0.33% to 2,990,052 units (SEC Form 4)

AMPH· Amphastar Pharmaceuticals Inc.
Health Care
Original source

Companies

  • AMPH
    Amphastar Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 21UpdateJefferies$22.00
  • Dec 9UpdateBarclays$30.00
  • Aug 12UpdateNeedham$36.00
  • May 12UpdateAnalyst$30.00
  • Feb 4UpdatePiper Sandler$36.00
  • Nov 22UpdateWells Fargo$55.00

Related

  • ANALYST3d
    Amphastar Pharmaceuticals downgraded by Jefferies with a new price target
  • SEC10d
    SEC Form DEFA14A filed by Amphastar Pharmaceuticals Inc.
  • SEC10d
    SEC Form DEF 14A filed by Amphastar Pharmaceuticals Inc.
  • NEWS18d
    Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.
  • INSIDER37d
    EVP CORP ADMIN CENTER Liawatidewi Yakob covered exercise/tax liability with 1,033 shares, decreasing direct ownership by 0.84% to 121,892 units (SEC Form 4)
  • INSIDER37d
    SENIOR EVP, PRODUCTION CENTER Zhou Rong covered exercise/tax liability with 1,225 shares, decreasing direct ownership by 0.71% to 171,554 units (SEC Form 4)
  • INSIDER37d
    CFO, EVP & TREASURER Peters William J covered exercise/tax liability with 1,973 shares, decreasing direct ownership by 1% to 175,063 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022